You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Screening for Alzheimer's Disease Based on Raman Spectroscopy of Blood

    SBC: Early Alzheimer's Diagnostics LLC            Topic: NIA

    Abstract - Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects an estimated 6.2 million Americans and the 6th leading cause of death in the U.S. AD is progressive and incurable; dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but in late-stage AD, individuals lose the ability to carry on a conversation and respond ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Next-Generation Expressive Personalized Voices for Speech-Generating Devices

    SBC: SYNFONICA LLC            Topic: NIDCD

    Project Summary/Abstract The creation of personalized synthetic voices has wide application in medical/rehabilitation settings for pa- tients who rely on a speech-generating device (SGD) for communication. One common application is voice banking, wherein a person who risks losing their voice, such as somebody with a neurodegenerative disease like Amyotrophic Lateral Sclerosis (ALS), records their ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Feasibility testing of a novel AI-enabled, cloud-based ECG diagnostic solution to enable fast and affordable diagnosis in long-term continuous ambulatory ECG monitoring

    SBC: ZBEATS, INC            Topic: NHLBI

    PROJECT SUMMARY. The proposed observational study is to evaluate the feasibility of a novel ECG monitoring system leveraging concurrent AI and cloud technologies in long-term continuous monitoring (LTCM) in the clinical environment. It does not intend to use any data or information from the investigational solution to interfere, intervene or affect any clinical decisions made for the participants. ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Accessible and Robust High-Throughput Western Blotting for Small Sample Sizes

    SBC: BLOTTING INNOVATIONS, LLC            Topic: 400

    PROJECT SUMMARY The goal of this Phase I STTR is for Blotting Innovations, LLC to establish feasibility of a commercializable mesowestern—a high-throughput, affordable western blotting technique that we recently developed. Western blotting is a technique for molecular-weight-resolved analysis of proteins and their post-translational modifications that is practiced today almost identically to whe ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Develop AAV9 gene replacement therapy for treating MPS I

    SBC: NEUROGT INC            Topic: 107

    Project Summary NeuroGT, Inc is a start-up company founded by Dr. Haiyan Fu, an associate professor in the Gene Therapy Center at University of North Carolina at Chapel Hill, with the mission of develop and commercialize effective gene therapy products to treat rare neurogenetic diseases in humans. The goal of this project is to develop an effective gene therapy product targeting the root cause fo ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Modified Caveolin-1 Scaffolding Domain Peptides with Improved Pharmacological Properties as Therapeutic Agents for Scleroderma Skin Disease

    SBC: FIBROTHERAPEUTICS INC            Topic: NIAMS

    Abstract Our long-term objective is to develop an effective treatment for scleroderma (systemic sclerosis, SSc) skin fibrosis. Caveolin-1 is a promising therapeutic target in fibrotic diseases. The profibrotic effects of caveolin-1 deficiency in cells and in mouse models is suppressed by a peptide equivalent to its active site (caveolin-1 scaffolding domain, CSD). However, CSD lacks suitable pharm ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. LAUR-201 (V-Smart®-TNV for Neuro-HIV): Novel V-Smart® Nanomedicine for Treatment of HAND

    SBC: LAUREN SCIENCES LLC            Topic: 105

    Lauren Sciences goal is to advance development of its innovative V-Smart® Nanomedicine for Neuro-HIV, LAUR- 201 (V-Smart®-Tenofovir for Neuro-HIV), as a disease-modifying therapeutic for the critical unmet medical needs of 50% of the 40 million HIV patients worldwide who, despite suppressive antiretroviral therapy (ART), suffer from HIV-associated neurocognitive disorders (HAND). Currently, ther ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Therapeutics for Interstitial Lung Disease: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development

    SBC: FIBROTHERAPEUTICS INC            Topic: NHLBI

    Abstract Our long-term goal is to improve on the limited choices for treating the many devastating diseases that together constitute the Interstitial Lung Diseases (ILD), the most prevalent of which are scleroderma and Idiopathic Pulmonary Fibrosis. As ILD affects those in late middle age trying to remain active, the market for a treatment will grow rapidly. Caveolin-1 is a promising therapeutic t ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Combination of CB101 and radiation therapy in head and neck squamous cell carcinoma

    SBC: Curebiotech, Inc.            Topic: 102

    Curebiotech, Inc., FOA # PA-21-262 Application number 1121483 PROJECT SUMMARYHead and neck squamous cell carcinoma (HNSCC) is the seventh leading cause of cancer-related mortality in the world. Radiation therapy (RT) is routinely used for patients with locoregionally advanced disease. The historical 5-year overall survival rates for locally advanced HNSCC after treatment with surgery, chemotherapy ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. The development of a multifunctional nanoenzyme for AD treatment

    SBC: AcePre, LLC            Topic: NIA

    Summary. The development of Alzheimer’s disease (AD) is the collective consequence of the toxicities induced by β-amyloid (Aβ) plaques, tau protein-formed neurofibrillary tangles, and malfunction of microglia due to inflammation and oxidative damage. Most AD therapeutics only target one of these key factors; the failed clinical trials proved the insufficiency of these individual approaches. In ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government